Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

274 questions in 25 reviews · Movement Disorders

current versions

No studies 13 · 4.7%Ungraded 7 · 2.6%Very low 66 · 24.1%Low 66 · 24.1%Moderate 87 · 31.8%High 35 · 12.8%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Intervention NR Headache (adverse effect, post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	RR 2.07 [0.2, 21.61]	1 study · 61 participants	Moderate
Intervention NR HRQOL (post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	no estimate extracted	1 study · 61 participants	Moderate
Intervention NR Subjective impact of fatigue on ADL, fatigue severity (post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	no estimate extracted	1 study · 34 participants	Moderate
Intervention NR Subjective impact of physical fatigue on ADL (post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	no estimate extracted	1 study · 34 participants	Moderate
Intervention NR Subjective impact of mental fatigue on ADL (post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	no estimate extracted	1 study · 34 participants	Moderate
Intervention NR Headache (adverse effect, post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	RR 0.24 [0.01, 4.62]	1 study · 31 participants	Moderate
Intervention NR Hypertension (adverse effect, post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	RR 6 [0.31, 115.56]	1 study · 31 participants	Moderate
Intervention NR Nausea (adverse effect, post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	RR 1.21 [0.08, 17.71]	1 study · 31 participants	Moderate
Intervention NR Headache (adverse effect,post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	RR 2.66 [0.82, 8.61]	1 study · 361 participants	Moderate
Intervention NR Tachycardia (adverse effect, post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	RR 0.4 [0.02, 9.12]	1 study · 31 participants	Moderate
Intervention NR Subjective impact of fatigue on ADL (post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	no estimate extracted	2 studies · 53 participants	Low
Intervention NR Subjective impact of physical fatigue on ADL (post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	no estimate extracted	1 study · 16 participants	Very low
Intervention NR Subjective impact of mental fatigue on ADL (post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	no estimate extracted	1 study · 16 participants	Low
Intervention NR Subjective fatigue severity (post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	no estimate extracted	1 study · 37 participants	Moderate
Intervention NR Anxiety (adverse effect, post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	RR 3.14 [0.35, 27.79]	2 studies · 50 participants	Moderate
Intervention NR Headache (adverse effect, post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	RR 0.58 [0.07, 4.95]	1 study · 13 participants	Moderate
Intervention NR Hypertension (adverse effect, post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	RR 3.43 [0.16, 71.36]	1 study · 13 participants	Moderate
Intervention NR Nausea (adverse effect, post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	RR 1.01 [0.11, 8.93]	2 studies · 50 participants	Moderate
Intervention NR Subjective impact of fatigue on ADL, fatigue severity (post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	no estimate extracted	1 study · 12 participants	Low
Intervention NR Hypertension (adverse effect, post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	RR 1 [0.28, 3.6]	1 study · 361 participants	Moderate
Intervention NR Nausea (adverse effect, post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	RR 3 [0.15, 61.74]	1 study · 12 participants	Very low
Intervention NR Orthostatic hypotension (adverse effect, post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	RR 3 [0.15, 61.74]	1 study · 12 participants	Very low
Intervention NR HRQOL (post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	no estimate extracted	1 study · 12 participants	Very low
Intervention NR Subjective impact of fatigue on ADL, fatigue severity (post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	no estimate extracted	2 studies · 57 participants	Low
Intervention NR HRQOL (post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	no estimate extracted	2 studies · 57 participants	Low
Intervention NR Nausea (adverse effect, post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	RR 1.85 [1.05, 3.27]	1 study · 361 participants	High
Intervention NR Subjective impact of fatigue on ADL, fatigue severity (post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	no estimate extracted	1 study · 36 participants	Moderate
Intervention NR Anxiety (adverse effect, post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	RR 0.33 [0.01, 7.72]	1 study · 40 participants	Moderate
Intervention NR Hypertension (adverse effect, post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	RR 0.33 [0.01, 7.72]	1 study · 40 participants	Moderate
Intervention NR Impulse control disorders (adverse effect, post‐intervention) · people with Parkinson's disease Interventions for fatigue in Parkinson's disease (2015) · Cochrane	RR 3 [0.13, 69.52]	1 study · 40 participants	Moderate
Creatine vs placebo UPDRS motor score · people with Parkinson's disease Creatine for Parkinson's disease (2014) · Cochrane	no estimate extracted	2 studies · 194 participants	Low
Creatine vs placebo UPDRS ADL score · people with Parkinson's disease Creatine for Parkinson's disease (2014) · Cochrane	0.37	2 studies · 194 participants	Low
Intervention NR Reduction in salivary flow Interventions for drooling in children with cerebral palsy (2012) · Cochrane	no estimate extracted	NR	Low
Intervention NR Reduction in frequency and severity of drooling Interventions for drooling in children with cerebral palsy (2012) · Cochrane	no estimate extracted	NR	Low
Intervention NR Adverse Effects to BoNT‐A Interventions for drooling in children with cerebral palsy (2012) · Cochrane	no estimate extracted	NR	Low
Intervention NR Non‐compliance with intervention Interventions for drooling in children with cerebral palsy (2012) · Cochrane	no estimate extracted	NR	Low
Intervention NR Reduction in salivary flow Interventions for drooling in children with cerebral palsy (2012) · Cochrane	no estimate extracted	NR	Low
Intervention NR Reduction in frequency and severity of drooling Interventions for drooling in children with cerebral palsy (2012) · Cochrane	no estimate extracted	NR	Low
Intervention NR Adverse effects of benztropine Interventions for drooling in children with cerebral palsy (2012) · Cochrane	no estimate extracted	NR	Low
Intervention NR Adverse effects of glycopyrrolate Interventions for drooling in children with cerebral palsy (2012) · Cochrane	no estimate extracted	NR	Low
Intervention NR Non‐compliance with intervention Interventions for drooling in children with cerebral palsy (2012) · Cochrane	no estimate extracted	NR	Low
Whole ‐body vibration vs an active physical therapy (short‐term effects) Body balance Functional Reach test · patients with neurodegenerative disease Whole‐body vibration training for patients with neurodegenerative disease (2012) · Cochrane	no estimate extracted	2 studies · 45 participants	Low
Whole ‐body vibration vs an active physical therapy (short‐term effects) Gait Timed Up and Go test · patients with neurodegenerative disease Whole‐body vibration training for patients with neurodegenerative disease (2012) · Cochrane	no estimate extracted	2 studies · 45 participants	Low
Whole‐ body vibration vs an active physical therapy (long‐term effects) Body balance Berg Balance Scale and Tinetti test · patients with neurodegenerative disease Whole‐body vibration training for patients with neurodegenerative disease (2012) · Cochrane	no estimate extracted	2 studies · 42 participants	Very low
Whole‐ body vibration vs an active physical therapy (long‐term effects) Gait Time Up and Go test and Stand‐walk‐sit test · patients with neurodegenerative disease Whole‐body vibration training for patients with neurodegenerative disease (2012) · Cochrane	no estimate extracted	2 studies · 42 participants	Very low
Whole‐ body vibration vs an active physical therapy (long‐term effects) UPDRS III UPDRS scale (motor score). Scale from: 0 to 56. · patients with neurodegenerative disease Whole‐body vibration training for patients with neurodegenerative disease (2012) · Cochrane	no estimate extracted	2 studies · 42 participants	Very low
Summary of findings: levodopa vs placebo Severity of symptoms (rating from 0 = not present to 10 = severe) · patients with restless legs syndrome Levodopa for the treatment of restless legs syndrome (2011) · Cochrane	no estimate extracted	2 studies · 48 participants	Moderate
Summary of findings: levodopa vs other dopamine agonists Total sleep time (TST) · patients with restless legs syndrome Levodopa for the treatment of restless legs syndrome (2011) · Cochrane	no estimate extracted	1 study · 11 participants	Very low
Summary of findings: levodopa vs other dopamine agonists Number of drop outs due to adverse events · patients with restless legs syndrome Levodopa for the treatment of restless legs syndrome (2011) · Cochrane	OR 0.59	3 studies · 504 participants	Moderate
Summary of findings: levodopa vs other dopamine agonists Clinical Global Impressions ‐ Improvement of condition (CGI‐I) Rating of 1 = very much improved to 7 = very much worse · patients with restless legs syndrome Levodopa for the treatment of restless legs syndrome (2011) · Cochrane	no estimate extracted	1 study · 344 participants	Moderate